scholarly journals LONG-TERM FOLLOW-UP OF 203 CHILDREN WITH HODGKIN'S DISEASE /HD/TREATED WITH MVPP AND INVOLVED-FIELD RADIOTHERAPY

1989 ◽  
Vol 26 (5) ◽  
pp. 525-525
Author(s):  
A Moryl-Bujakowska ◽  
W Balwierz ◽  
J Armata ◽  
T Depowska ◽  
U Radwanska ◽  
...  
Author(s):  
Stephan Bodis ◽  
Madeleine Kraus ◽  
Geraldine Pinkus ◽  
Barbara Silver ◽  
Peter Mauch

1996 ◽  
Vol 37 (1P1) ◽  
pp. 323-326 ◽  
Author(s):  
R. Nyman ◽  
G. Forsgren ◽  
B. Glimelius

Purpose: Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging. Material and Methods: Ten patients, with substantial residual mediastinal masses of low signal intensity (SI) in the T2-weighted image (T2WI), were reinvestigated with MR 19–79 months after completing treatment of Hodgkin's disease. All patients were in complete remission. Results: During the follow-up period, the masses had decreased in size by 0–95% (median 67%) as compared to their initial post-therapy size. The SI continued to be low in the T2WI and was unaffected by the degree of size reduction. Conclusion: It is speculated that these mainly fibrotic residual masses undergo slow degradation of the fibrotic part and/or resorption of remaining inflammatory tissue. It is important to understand the natural, long-term MR imaging changes of these residual masses in order more easily to recognize tumour recurrence or other pathologic conditions.


1983 ◽  
Vol 69 (5) ◽  
pp. 463-467
Author(s):  
Teodoro Chisesi ◽  
Orlando Ricciardi ◽  
Sandra Dal Fior ◽  
Francesco Cappellari ◽  
Franco Pozza ◽  
...  

Forty-nine patients with previously untreated advanced Hodgkin's disease were treated in our Institution between 1973 and 1981. Treatment modalities of these patients were reviewed, and they were divided into 3 groups according to the treatment employed: 13 patients received MOPP only, 22 patients received MOPP plus involved field radiotherapy, and 14 received alternating MOPP/ABVD chemotherapy. The response rates for the 3 groups were respectively 38.5%, 63.6% and 78.6%. A longer follow-up is needed to assess a significant difference in survival curves. The advantages of adjuvant radiotherapy and alternating non-cross-resistant drugs in advanced Hodgkin's disease are discussed.


1983 ◽  
Vol 1 (7) ◽  
pp. 432-439 ◽  
Author(s):  
N Tannir ◽  
F Hagemeister ◽  
W Velasquez ◽  
F Cabanillas

Thirty-six consecutive patients with advanced recurrent Hodgkin's disease resistant to chemotherapy with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) were treated with doxorubicin (Adriamycin), bleomycin, (dacarbazine) DTIC, (lomustine) CCNU, and prednisone (ABDIC). Among the 34 patients evaluable for response, complete remission occurred in 35% and partial remission in 35%. The achievement of complete remission during primary MOPP induction was a statistically significant prognostic factor that predicted complete remission with ABDIC (p less than 0.01). The median time to complete remission was 2 months (range 1-11 mo). The median relapse-free survival time for complete responders is 47 months, and an estimated 53% of all patients who achieve complete remission are projected to be alive, free of disease off therapy at 3 years from initiation of ABDIC. The median survival of all patients is 24 months. The median survival of complete responders, partial responders, and nonresponders is 70, 17, and 4 months, respectively. The survival curve for complete responders is significantly different from that for partial responders (p less than 0.01); the survival curve for partial responders is also significantly different from that of nonresponders (p less than 0.01). Toxicity of ABDIC was acceptable; only one patient died from complications of myelosuppression. Our results indicate that ABDIC is a potentially curative regimen for a fraction of patients with MOPP-resistant Hodgkin's disease who achieve complete remission with prior MOPP therapy. It also prolongs the survival of patients who do not achieve complete remission with prior MOPP therapy.


Author(s):  
Zhongxing Liao ◽  
Chul S. Ha ◽  
Lillian M. Fuller ◽  
Fredrick B. Hagemeister ◽  
Fernando Cabanillas ◽  
...  

BMJ ◽  
1982 ◽  
Vol 285 (6355) ◽  
pp. 1612-1613 ◽  
Author(s):  
J H Waxman ◽  
Y A Terry ◽  
P F Wrigley ◽  
J S Malpas ◽  
L H Rees ◽  
...  

Cancer ◽  
1979 ◽  
Vol 43 (4) ◽  
pp. 1234-1244 ◽  
Author(s):  
Barth Hoogstraten ◽  
Oliver Glidewell ◽  
James F. Holland ◽  
Johannes Blom ◽  
Leon Stutzman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document